Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients (HF-ACZ)
Primary Purpose
Heart Failures
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Acetazolamide
Placebo
Sponsored by

About this trial
This is an interventional basic science trial for Heart Failures
Eligibility Criteria
Inclusion Criteria (Heart failure patients)
- Left ventricular ejection fraction (EF) <50%, or heart failure with preserved EF
- Age 18-89
Exclusion Criteria:
- severe obstructive respiratory disease
- unstable heart failure status
- recent use of positive airway pressure therapy
- current use of opioids, benzodiazepines
- severe kidney disease
- severe anemia
Sites / Locations
- Brigham and Women's Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Acetazolamide
Sugar pill
Arm Description
Outcomes
Primary Outcome Measures
The Severity of Sleep Disordered Breathing (Apnea-hypopnea Index, AHI)
The frequency of apneas and hypopneas (apnea-hypopnea index) was assessed. The primary measure was the value for non-REM supine sleep. A higher value indicates more severe sleep apnea. A value above 15 indicates the presence of moderate-to-severe sleep apnea.
Secondary Outcome Measures
Ventilatory Chemoreflex Sensitivity, "Loop Gain" Using Carbon Dioxide Pulses
Chemoreflex "loop gain" was assessed according to Sands SA et al AJRCCM 2017 Jan 15;195(2):237-246. Loop gain is a unitless ratio measure that describes the magnitude of the increase in ventilation that occurs in response to a prior reduction in ventilation ("disturbance") and has units of L/min per L/min. A larger value indicates a more sensitive and unstable control system predisposing to oscillatory breathing. Loop gain was measured on the time scale of 1 min (i.e. response to a 1 cycle/min sinusoidal disturbance, referred to as "LG1"). The procedure involved brief administration of 7% carbon dioxide in air for 0.5 min ("pulses"); tests were repeated every 3 min for 30 min while measuring ventilation and carbon dioxide levels at the nose with patients awake and supine.
measured using 0.5 min pulses of carbon dioxide.
Sympathetic Activity (Urinary Norepinephrine)
Urinary norepinephrine levels overnight
Left-atrial Volume
Left-atrial volume index, echocardiography, bi-plane method. Lower values were considered a favorable outcome. We considered values ≤28 mL/m^2 to indicate normal left atrial volume. Values indicating graded left atrial enlargement were described as follows: mild (29-33 mL/m^2), moderate (34-39 mL/m^2), severe (≥40 mL/m^2).
Brain Natriuretic Peptide (NT-proBNP)
Brain natriuretic peptide (NT-proBNP) in morning
Pittsburgh Sleep Quality Index
Pittsburgh Sleep Quality Index is a measure of self-reported sleep quality containing 19 questions that make up 7 component scores that are added to provide a total score. Total scores range from 0-21 (units on a scale) with higher scores representing reduced sleep quality. A score of 5 or more is interpreted as reduced sleep quality. The total score is reported.
Full Information
NCT ID
NCT01377987
First Posted
June 20, 2011
Last Updated
May 16, 2018
Sponsor
David Andrew Wellman
Collaborators
American Heart Association, National Institutes of Health (NIH)
1. Study Identification
Unique Protocol Identification Number
NCT01377987
Brief Title
Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients
Acronym
HF-ACZ
Official Title
Physiological Study to Predict Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients
Study Type
Interventional
2. Study Status
Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
August 2011 (undefined)
Primary Completion Date
December 2016 (Actual)
Study Completion Date
December 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
David Andrew Wellman
Collaborators
American Heart Association, National Institutes of Health (NIH)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The ultimate goal is to improve our understanding of the pathophysiology and resistance to effective treatment of sleep disordered breathing in patients with heart failure, with a focus on selecting patients that will benefit specifically from acetazolamide treatment.
The study addresses three primary hypotheses: 1) Acetazolamide treatment will reduce the apnea-hypopnea index and improve markers of heart-failure severity in heart-failure patients with sleep apnea. 2) Acetazolamide will provide the greatest improvement in patients with the most severe ventilatory control instability (strongest chemoreflex response to carbon dioxide; highest loop gain). 3) Acetazolamide will act primarily via stabilizing ventilatory control (reducing loop gain), rather than via improvement to upper airway anatomy, pulmonary congestion, and cardiac function.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failures
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
29 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Acetazolamide
Arm Type
Experimental
Arm Title
Sugar pill
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Acetazolamide
Other Intervention Name(s)
Diamox
Intervention Description
4 mg/kg, once daily before bed, for 7 days
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
4 mg/kg, once daily before bed, for 7 days
Primary Outcome Measure Information:
Title
The Severity of Sleep Disordered Breathing (Apnea-hypopnea Index, AHI)
Description
The frequency of apneas and hypopneas (apnea-hypopnea index) was assessed. The primary measure was the value for non-REM supine sleep. A higher value indicates more severe sleep apnea. A value above 15 indicates the presence of moderate-to-severe sleep apnea.
Time Frame
1 week
Secondary Outcome Measure Information:
Title
Ventilatory Chemoreflex Sensitivity, "Loop Gain" Using Carbon Dioxide Pulses
Description
Chemoreflex "loop gain" was assessed according to Sands SA et al AJRCCM 2017 Jan 15;195(2):237-246. Loop gain is a unitless ratio measure that describes the magnitude of the increase in ventilation that occurs in response to a prior reduction in ventilation ("disturbance") and has units of L/min per L/min. A larger value indicates a more sensitive and unstable control system predisposing to oscillatory breathing. Loop gain was measured on the time scale of 1 min (i.e. response to a 1 cycle/min sinusoidal disturbance, referred to as "LG1"). The procedure involved brief administration of 7% carbon dioxide in air for 0.5 min ("pulses"); tests were repeated every 3 min for 30 min while measuring ventilation and carbon dioxide levels at the nose with patients awake and supine.
measured using 0.5 min pulses of carbon dioxide.
Time Frame
1 week
Title
Sympathetic Activity (Urinary Norepinephrine)
Description
Urinary norepinephrine levels overnight
Time Frame
1 week
Title
Left-atrial Volume
Description
Left-atrial volume index, echocardiography, bi-plane method. Lower values were considered a favorable outcome. We considered values ≤28 mL/m^2 to indicate normal left atrial volume. Values indicating graded left atrial enlargement were described as follows: mild (29-33 mL/m^2), moderate (34-39 mL/m^2), severe (≥40 mL/m^2).
Time Frame
1 week
Title
Brain Natriuretic Peptide (NT-proBNP)
Description
Brain natriuretic peptide (NT-proBNP) in morning
Time Frame
1 week
Title
Pittsburgh Sleep Quality Index
Description
Pittsburgh Sleep Quality Index is a measure of self-reported sleep quality containing 19 questions that make up 7 component scores that are added to provide a total score. Total scores range from 0-21 (units on a scale) with higher scores representing reduced sleep quality. A score of 5 or more is interpreted as reduced sleep quality. The total score is reported.
Time Frame
1 week
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria (Heart failure patients)
Left ventricular ejection fraction (EF) <50%, or heart failure with preserved EF
Age 18-89
Exclusion Criteria:
severe obstructive respiratory disease
unstable heart failure status
recent use of positive airway pressure therapy
current use of opioids, benzodiazepines
severe kidney disease
severe anemia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Wellman, MD, PhD
Organizational Affiliation
Brigham and Women's Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Atul Malhotra, MD
Organizational Affiliation
Brigham and Women's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients
We'll reach out to this number within 24 hrs